Vutrisiran — ATTR amyloidosis
A quarterly injection that reduces the protein driving ATTR amyloidosis.
ATTR amyloidosis is caused by a misfolded transthyretin protein depositing in nerves and heart muscle. Vutrisiran is a small interfering RNA that reduces transthyretin production at the source, given as a subcutaneous injection every three months.
For patients in markets where the product is not yet registered, the zone’s special-access pathway can make it reachable well before a national approval. Diagnosis must be confirmed by genetic testing and, where relevant, cardiac imaging.
What it does not do
- Confirming the diagnosis — and the genotype — comes first. This is not a treatment for other forms of amyloidosis.
- It slows progression; it does not reverse existing nerve or heart damage.
- Patients already stable on an alternative therapy should discuss switching with their own physician before travelling.
These limits are written by us, not by the hospital. If a provider presents this therapy without any of them, treat that as a warning sign.
| Indication | Hereditary ATTR amyloidosis with polyneuropathy or cardiomyopathy |
| Approved in | United States, European Union, Japan |
| Status in China | First clinical use in China delivered in the zone |
| Assessment required | Yes — physician assessment first |
| Delivered at | 2 hospital(s) |
Delivered at
Ruijin Hospital Hainan
Ruijin's Hainan campus exports the Shanghai department structure and case-management standards, including the airway basal-cell programme for COPD.
Boao Super Hospital
The zone's shared platform. Most international patients start here because the special-access catalogue and the multidisciplinary teams are concentrated in one building.
Tell us the therapy by name, and we will check it.
Availability moves with batches and indications. A two-line enquiry is enough for us to confirm whether it is reachable this quarter.